25-27 September 2025
✔️Paediatric residents, trainees, or early-career paediatricians.
✔️Individuals committed to child health and the advancement of paediatrics.
✔️Active members of national or European paediatric organisations.
✔️Professionals with current or future potential for leadership, advocacy, or regulatory roles.
✔️ Full access to all training sessions and Academy activities
✔️ Accommodation for 2 nights (25–27 September) at the Radisson Blu Hotel Leipzig
✔️ Networking opportunities with peers and expert faculty
Places are strictly limited to 30 participants to ensure an intensive and personalised experience.
The EAP Leadership Academy 2025 is proudly supported by:
Increasing the positive impact of nutrition.
Transforming the practice of medicine through breakthrough science.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.